MIF-1 is a research compound. It is not approved by the FDA or any regulatory body for human use. This article is for educational and informational purposes only. Nothing here constitutes medical advice. Consult a qualified physician before considering any peptide use.
MIF-1 (Pro-Leu-Gly-NH2 (Melanocyte-inhibiting factor-1)) is a Neuropeptide, dopamine receptor modulator. Endogenous tripeptide derived from cleavage of oxytocin, produced primarily by the hypothalamus. It is researched for antidepressant effects, nootropic enhancement, anti-Parkinsonian action, dopamine modulation. Common dosages range from 1-10 mg administered once daily.
What Is MIF-1?
MIF-1 (Pro-Leu-Gly-NH2 (Melanocyte-inhibiting factor-1)) is a Neuropeptide, dopamine receptor modulator. Endogenous tripeptide derived from cleavage of oxytocin, produced primarily by the hypothalamus. Also known as MIF-1, melanostatin, prolylleucylglycinamide, it has been studied for its potential effects on antidepressant effects, nootropic enhancement, anti-Parkinsonian action, dopamine modulation.
Unique as an allosteric dopamine modulator rather than agonist — enhances endogenous dopamine signaling without directly activating receptors, a mechanism distinct from most dopaminergic drugs. In the research community, MIF-1 has gained attention for its distinctive profile.
How Does MIF-1 Work?
Acts as a positive allosteric modulator of D2 and D4 dopamine receptors while simultaneously blocking opioid receptor activation. Inhibits release of alpha-MSH and potentiates melatonin activity, creating a complex neurochemical profile affecting mood, motor function, and reward signaling.
This multi-pathway activity helps explain why MIF-1 shows potential across several different applications.
What Does the Research Say About MIF-1?
Extensively studied in animal models showing antidepressant and nootropic effects through multiple neurotransmitter systems. Multiple peer-reviewed studies from 1980s-1990s. No human clinical trials.
Researchers should consult the latest peer-reviewed literature for the most current findings.
What Is the Recommended MIF-1 Dosage?
Standard MIF-1 dosing: 1-10 mg, administered once daily via subcutaneous injection (poorly active orally).
Half-life: resistant to bloodstream metabolism; crosses blood-brain barrier. Cycle length: not established; short protocols in research.
Use our peptide dosing calculator for exact reconstitution ratios.
Calculate Your MIF-1 Dose
Use our free peptide dosing calculator to get exact reconstitution math and syringe units for MIF-1.
Open Calculator →What Are the Side Effects of MIF-1?
Limited human data. Inverted U-curve response — loses efficacy at very high doses. No serious adverse effects documented.
MIF-1 is not fda-approved. research chemical.
Can You Stack MIF-1 With Other Peptides?
Pairs with dopamine-enhancing compounds (L-DOPA) to amplify dopaminergic effects through allosteric modulation.
What Is the Bottom Line on MIF-1?
MIF-1 is a Neuropeptide, dopamine receptor modulator researched for antidepressant effects, nootropic enhancement, anti-Parkinsonian action, dopamine modulation. Standard protocols use 1-10 mg once daily for not established; short protocols in research.
Source from COA-tested vendors. Read our beginner's guide for more, or use the dosing calculator to plan your protocol.
Complete Guide
MIF-1 : Benefits, Dosage, Side Effects & Research
Related Reading
- MIF-1 Dosage Guide
- MIF-1 Benefits
- MIF-1 Side Effects
- MIF-1 Stacking Guide
- MIF-1 Cycle Guide
- MIF-1 Research
Research-Grade Sourcing
If you're going to research MIF-1, source matters. These are the suppliers WolveStack has vetted for purity and third-party testing.
Frequently Asked Questions
What is MIF-1?
MIF-1 (Pro-Leu-Gly-NH2 (Melanocyte-inhibiting factor-1)) is a Neuropeptide, dopamine receptor modulator. Endogenous tripeptide derived from cleavage of oxytocin, produced primarily by the hypothalamus. It is researched for antidepressant effects, nootropic enhancement, anti-Parkinsonian action, dopamine modulation.
What is the recommended MIF-1 dosage?
Common dosages: 1-10 mg administered once daily via subcutaneous injection (poorly active orally). Cycle length: not established; short protocols in research. Half-life: resistant to bloodstream metabolism; crosses blood-brain barrier. Use our peptide calculator for exact reconstitution math.
What are the side effects of MIF-1?
Limited human data. Inverted U-curve response — loses efficacy at very high doses. No serious adverse effects documented.
Is MIF-1 safe?
MIF-1 has shown a preliminary safety profile in research. Not FDA-approved. Research chemical. All research should follow appropriate safety protocols.